Author

Ethan M. Niemeyer

University of Minnesota

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Beau R. WebberiD· 2 shared Branden S. MoriarityiD· 2 shared Bryce J. WickiD· 2 shared Joseph G. SkeateiD· 2 shared Mitchell G. KluesneriD· 2 shared Nicholas J. SlipekiD· 2 shared Alexandria K. Gilkey· 1 shared Bibekananda KariD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Beau R. WebberORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioengineeringMolecular TherapyPeer-reviewedJul 18, 2026

A Singular Base Editing Platform for Polyfunctional Multiplex Engineering of Immune Cells

Joseph G. Skeate, Nicholas J. Slipek, Walker S. Lahr…·Beau R. Webber

This paper develops a base editing platform to efficiently and safely engineer CAR T cells with multiple gene knockouts and insertions.

3 citations

humanCRISPR screen

𝕏 PostBluesky

ImmunologyMolecular Therapy OncologyPeer-reviewedSep 24, 2025

Installation of Dominant-Negative Mutations in FAS and TGFβR2 via Base Editing in Primary T Cells

Bryce J. Wick, Mitchell G. Kluesner, Nicholas J. Slipek…·Branden S. Moriarity

This paper uses base editing to introduce dominant-negative mutations in FAS and TGFβR2 in primary T cells, enhancing their anti-tumor efficacy and persistence in solid tumor models.

DOI 10.1016/j.omton.2025.201063

humanexperimental assay

𝕏 PostBluesky